BioInvent International AB (publ) (STO:BINV)
24.50
+1.45 (6.29%)
Sep 2, 2026, 5:29 PM CET
BioInvent International AB Employees
BioInvent International AB had 108 employees as of June 30, 2026. The number of employees decreased by 14 or -11.48% compared to the same quarter last year.
Employees
108
Change
-14
Growth
-11.48%
Revenue / Employee
301.02K SEK
Profits / Employee
-4.60M SEK
Market Cap
1.52B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 108 | -14 | -11.48% |
| Mar 31, 2026 | 112 | -6 | -5.08% |
| Dec 31, 2025 | 109 | -5 | -4.39% |
| Sep 30, 2025 | 124 | 9 | 7.83% |
| Jun 30, 2025 | 122 | 10 | 8.93% |
| Mar 31, 2025 | 118 | 9 | 8.26% |
| Dec 31, 2024 | 114 | 3 | 2.70% |
| Sep 30, 2024 | 115 | 7 | 6.48% |
| Jun 30, 2024 | 112 | 9 | 8.74% |
| Mar 31, 2024 | 109 | 7 | 6.86% |
| Dec 31, 2023 | 111 | 17 | 18.09% |
| Sep 30, 2023 | 108 | 15 | 16.13% |
| Jun 30, 2023 | 103 | 14 | 15.73% |
| Mar 31, 2023 | 102 | 16 | 18.60% |
| Dec 31, 2022 | 94 | 10 | 11.90% |
| Sep 30, 2022 | 93 | 8 | 9.41% |
| Jun 30, 2022 | 89 | 11 | 14.10% |
| Mar 31, 2022 | 86 | 12 | 16.22% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Oncopeptides AB | 77 |
| Egetis Therapeutics AB | 56 |
| Vicore Pharma Holding AB | 46 |
| Saniona AB | 43 |
| Genovis AB (publ.) | 42 |
| AlzeCure Pharma AB | 10 |
| SynAct Pharma AB | 8 |
| Medivir AB | 7 |
BioInvent International AB News
- 6 days ago - BioInvent International AB Quarterly report: Q2 2026 - Filings
- 13 days ago - BioInvent Announces Publication of Preclinical Manuscript on BI-1808 and BI-1910 in Cancer Research - Accesswire
- 26 days ago - BioInvent International: BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer - Finanz Nachrichten
- 26 days ago - BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer - Accesswire
- 5 weeks ago - BioInvent International: BioInvent Publication in JECCR: Tailored Fc?R Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models - Finanz Nachrichten
- 5 weeks ago - BioInvent Publication in JECCR: Tailored FcγR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models - Accesswire
- 6 weeks ago - BioInvent International: BioInvent's BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026 - Finanz Nachrichten
- 6 weeks ago - BioInvent's BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026 - Accesswire